{"count": 30, "results": [{"_id": "33798839", "pmid": 33798839, "title": "Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis.", "journal": "Placenta", "authors": ["Anness AR", "Baldo A", "Webb DR", "Khalil A", "Robinson TG", "Mousa HA"], "date": "2021-04-01T00:00:00Z", "doi": "10.1016/j.placenta.2021.02.021", "meta_date_publication": "2021 Apr", "meta_volume": "107", "meta_issue": "", "meta_pages": "51-58", "score": 50262.285, "text_hl": "Effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on biomarkers of placental- mediated @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@disease@@@: A systematic review and meta-analysis.", "citations": {"NLM": "Anness AR, Baldo A, Webb DR, Khalil A, Robinson TG, Mousa HA. Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis. Placenta. 2021 Apr;107():51-58. PMID: 33798839", "BibTeX": "@article{33798839, title={Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis.}, author={Anness AR and Baldo A and Webb DR and Khalil A and Robinson TG and Mousa HA}, journal={Placenta}, volume={107}, pages={51-58}}"}}, {"_id": "37387358", "pmid": 37387358, "pmcid": "PMC10328035", "title": "Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial", "journal": "Diab Vasc Dis Res", "authors": ["Chen D", "Jenkins AJ", "Greenlaw N", "Dudman K", "Fernandes T", "Carty DM", "Hughes AD", "Januszewski AS", "Stehouwer CD", "Petrie JR"], "date": "2023-05-01T00:00:00Z", "doi": "10.1177/14791641231183634", "meta_date_publication": "2023 May-Jun", "meta_volume": "20", "meta_issue": "3", "meta_pages": "14791641231183634", "score": 50257.996, "text_hl": "Cardiometabolic risk factors, peripheral arterial tonometry and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in adults with @DISEASE_Diabetes_Mellitus_Type_1 @DISEASE_MESH:D003922 @@@type 1 diabetes@@@ participating in the REducing with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MetfOrmin@@@ Vascular @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@Adverse Lesions@@@ trial", "citations": {"NLM": "Chen D, Jenkins AJ, Greenlaw N, Dudman K, Fernandes T, Carty DM, Hughes AD, Januszewski AS, Stehouwer CD, Petrie JR. Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial Diab Vasc Dis Res. 2023 May-Jun;20(3):14791641231183634. PMID: 37387358", "BibTeX": "@article{37387358, title={Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial}, author={Chen D and Jenkins AJ and Greenlaw N and Dudman K and Fernandes T and Carty DM and Hughes AD and Januszewski AS and Stehouwer CD and Petrie JR}, journal={Diab Vasc Dis Res}, volume={20}, number={3}, pages={14791641231183634}}"}}, {"_id": "35890085", "pmid": 35890085, "pmcid": "PMC9318003", "title": "Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses", "journal": "Pharmaceuticals (Basel)", "authors": ["Barrios-Bernal P", "Zatarain-Barrón ZL", "Hernández-Pedro N", "Orozco-Morales M", "Olivera-Ramírez A", "Ávila-Moreno F", "Colín-González AL", "Cardona AF", "Rosell R", "Arrieta O"], "date": "2022-06-24T00:00:00Z", "doi": "10.3390/ph15070786", "meta_date_publication": "2022 Jun 24", "meta_volume": "15", "meta_issue": "7", "meta_pages": "", "score": 50255.203, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has been under basic and clinical study as an oncological repurposing pharmacological agent for several years, stemming from observational studies which consistently evidenced that subjects who were treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ had a reduced risk for development of @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ throughout their lives, as well as improved survival outcomes when diagnosed with @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@neoplastic diseases@@@. ", "citations": {"NLM": "Barrios-Bernal P, Zatarain-Barrón ZL, Hernández-Pedro N, Orozco-Morales M, Olivera-Ramírez A, Ávila-Moreno F, Colín-González AL, Cardona AF, Rosell R, Arrieta O. Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses Pharmaceuticals (Basel). 2022 Jun 24;15(7):. PMID: 35890085", "BibTeX": "@article{35890085, title={Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses}, author={Barrios-Bernal P and Zatarain-Barrón ZL and Hernández-Pedro N and Orozco-Morales M and Olivera-Ramírez A and Ávila-Moreno F and Colín-González AL and Cardona AF and Rosell R and Arrieta O}, journal={Pharmaceuticals (Basel)}, volume={15}, number={7}}"}}, {"_id": "39446178", "pmid": 39446178, "title": "Metformin Attenuates Vocal Fold Fibrosis via AMPK Signaling.", "journal": "Inflammation", "authors": ["Cai J", "Fang L", "Zhou P", "Wu J", "Song Y", "Tuohuti A", "Sun Y", "Chen X"], "date": "2024-10-24T00:00:00Z", "doi": "10.1007/s10753-024-02165-5", "meta_date_publication": "2024 Oct 24", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50248.574, "text_hl": "Given the demonstrated efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in treating various @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@fibrotic diseases@@@, we hypothesized that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could reduce @DISEASE_Vocal_Cord_Paralysis @DISEASE_MESH:D014826 @@@vocal fold fibrosis@@@ via the AMPK signaling pathway. ", "citations": {"NLM": "Cai J, Fang L, Zhou P, Wu J, Song Y, Tuohuti A, Sun Y, Chen X. Metformin Attenuates Vocal Fold Fibrosis via AMPK Signaling. Inflammation. 2024 Oct 24;():. PMID: 39446178", "BibTeX": "@article{39446178, title={Metformin Attenuates Vocal Fold Fibrosis via AMPK Signaling.}, author={Cai J and Fang L and Zhou P and Wu J and Song Y and Tuohuti A and Sun Y and Chen X}, journal={Inflammation}}"}}, {"_id": "35379238", "pmid": 35379238, "pmcid": "PMC8981770", "title": "Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial", "journal": "Cardiovasc Diabetol", "authors": ["Stultiens JMG", "Top WMC", "Kimenai DM", "Lehert P", "Bekers O", "Stehouwer CDA", "Kooy A", "Meex SJR"], "date": "2022-04-04T00:00:00Z", "doi": "10.1186/s12933-022-01482-z", "meta_date_publication": "2022 Apr 4", "meta_volume": "21", "meta_issue": "1", "meta_pages": "49", "score": 50248.492, "text_hl": "Thorough statistical analysis of hs-@GENE_TNNI3 @GENE_7137 @@@cTnI@@@ and hs-@GENE_TNNT2 @GENE_7139 @@@cTnT@@@ levels in the HOME cohort, which previously reported reduced @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@macrovascular disease@@@ risk as a result of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment, did not reveal evidence of a clinically relevant effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment on these cardiac biomarkers, when compared with placebo. ", "citations": {"NLM": "Stultiens JMG, Top WMC, Kimenai DM, Lehert P, Bekers O, Stehouwer CDA, Kooy A, Meex SJR. Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial Cardiovasc Diabetol. 2022 Apr 4;21(1):49. PMID: 35379238", "BibTeX": "@article{35379238, title={Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial}, author={Stultiens JMG and Top WMC and Kimenai DM and Lehert P and Bekers O and Stehouwer CDA and Kooy A and Meex SJR}, journal={Cardiovasc Diabetol}, volume={21}, number={1}, pages={49}}"}}, {"_id": "39309781", "pmid": 39309781, "title": "Metformin dampens the progression of cholangiofibrosis induced by thioacetamide using deep learning.", "journal": "Heliyon", "authors": ["Li C", "Deng Y", "Pan Y", "Liao X", "Xie H", "Xue X", "Yu S", "Yu W", "Yu G"], "date": "2024-09-07T00:00:00Z", "doi": "10.1016/j.heliyon.2024.e37347", "meta_date_publication": "2024 Sep 30", "meta_volume": "10", "meta_issue": "18", "meta_pages": "e37347", "score": 50247.227, "text_hl": "Purpose: The consistent use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been linked to a reduced incidence of @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@neoplastic diseases@@@ among @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ populations. ", "citations": {"NLM": "Li C, Deng Y, Pan Y, Liao X, Xie H, Xue X, Yu S, Yu W, Yu G. Metformin dampens the progression of cholangiofibrosis induced by thioacetamide using deep learning. Heliyon. 2024 Sep 30;10(18):e37347. PMID: 39309781", "BibTeX": "@article{39309781, title={Metformin dampens the progression of cholangiofibrosis induced by thioacetamide using deep learning.}, author={Li C and Deng Y and Pan Y and Liao X and Xie H and Xue X and Yu S and Yu W and Yu G}, journal={Heliyon}, volume={10}, number={18}, pages={e37347}}"}}, {"_id": "36147352", "pmid": 36147352, "pmcid": "PMC9485720", "title": "Effectiveness and mechanism of metformin in animal models of pulmonary fibrosis: A preclinical systematic review and meta-analysis", "journal": "Front Pharmacol", "authors": ["Wu X", "Xiao X", "Chen X", "Yang M", "Hu Z", "Shuai S", "Fu Q", "Yang H", "Du Q"], "date": "2022-09-06T00:00:00Z", "doi": "10.3389/fphar.2022.948101", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "948101", "score": 50241.043, "text_hl": " Background: @DISEASE_Pulmonary_Fibrosis @DISEASE_MESH:D011658 @@@Pulmonary fibrosis@@@ (PF) is a @DISEASE_Lung_Diseases @DISEASE_MESH:D008171 @@@lung disease@@@ with no curative drug, characterized by a progressive decrease in lung function. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ (@GENE_SLTM @GENE_79811 @@@MET@@@) is a hypoglycemic agent with the advantages of high safety and low cost and has been used in several in vivo trials to treat @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@fibrotic diseases@@@.", "citations": {"NLM": "Wu X, Xiao X, Chen X, Yang M, Hu Z, Shuai S, Fu Q, Yang H, Du Q. Effectiveness and mechanism of metformin in animal models of pulmonary fibrosis: A preclinical systematic review and meta-analysis Front Pharmacol. 2022;13():948101. PMID: 36147352", "BibTeX": "@article{36147352, title={Effectiveness and mechanism of metformin in animal models of pulmonary fibrosis: A preclinical systematic review and meta-analysis}, author={Wu X and Xiao X and Chen X and Yang M and Hu Z and Shuai S and Fu Q and Yang H and Du Q}, journal={Front Pharmacol}, volume={13}, pages={948101}}"}}, {"_id": "32903813", "pmid": 32903813, "pmcid": "PMC7438907", "title": "Eye Drops of Metformin Prevents Fibrosis After Glaucoma Filtration Surgery in Rats via Activating AMPK/Nrf2 Signaling Pathway", "journal": "Front Pharmacol", "authors": ["Li X", "Leng Y", "Jiang Q", "Wang Z", "Luo P", "Zhang C", "Chen L", "Wang Y", "Wang H", "Yue X", "Shen C", "Zhou Y", "Shi C", "Xie L"], "date": "2020-07-31T00:00:00Z", "doi": "10.3389/fphar.2020.01038", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "1038", "score": 50240.88, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has effective therapeutic effects in anti-@DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ and anti-@<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@fibrotic diseases@@@. ", "citations": {"NLM": "Li X, Leng Y, Jiang Q, Wang Z, Luo P, Zhang C, Chen L, Wang Y, Wang H, Yue X, Shen C, Zhou Y, Shi C, Xie L. Eye Drops of Metformin Prevents Fibrosis After Glaucoma Filtration Surgery in Rats via Activating AMPK/Nrf2 Signaling Pathway Front Pharmacol. 2020;11():1038. PMID: 32903813", "BibTeX": "@article{32903813, title={Eye Drops of Metformin Prevents Fibrosis After Glaucoma Filtration Surgery in Rats via Activating AMPK/Nrf2 Signaling Pathway}, author={Li X and Leng Y and Jiang Q and Wang Z and Luo P and Zhang C and Chen L and Wang Y and Wang H and Yue X and Shen C and Zhou Y and Shi C and Xie L}, journal={Front Pharmacol}, volume={11}, pages={1038}}"}}, {"_id": "34396450", "pmid": 34396450, "pmcid": "PMC8383039", "title": "Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4", "journal": "Mol Med Rep", "authors": ["Shi Y", "Hou SA"], "date": "2021-10-01T00:00:00Z", "doi": "10.3892/mmr.2021.12351", "meta_date_publication": "2021 Oct", "meta_volume": "24", "meta_issue": "4", "meta_pages": "", "score": 50240.844, "text_hl": "In conclusion, the present study indicated that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ activated @GENE_PRKAA2 @GENE_78975 @@@AMPK@@@ to inhibit the expression of @GENE_NOX4 @GENE_85431 @@@NOX4@@@, leading to a decrease in @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@myocardial oxidative damage@@@ and apoptosis, thus alleviating @DISEASE_Reperfusion_Injury @DISEASE_MESH:D015427 @@@reperfusion injury@@@.", "citations": {"NLM": "Shi Y, Hou SA. Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4 Mol Med Rep. 2021 Oct;24(4):. PMID: 34396450", "BibTeX": "@article{34396450, title={Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4}, author={Shi Y and Hou SA}, journal={Mol Med Rep}, volume={24}, number={4}}"}}, {"_id": "36217796", "pmid": 36217796, "title": "Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2/TG2 axis.", "journal": "Nephrology (Carlton)", "authors": ["Kolligundla LP", "Kavvuri R", "Singh AK", "Mukhi D", "Pasupulati AK"], "date": "2023-01-01T00:00:00Z", "doi": "10.1111/nep.14121", "meta_date_publication": "2023 Jan", "meta_volume": "28", "meta_issue": "1", "meta_pages": "60-71", "score": 50239.434, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ could be explored to treat @<m>DISEASE_Disease</m> @DISEASE_MESH:D004194 @@@proteinuric diseases@@@ such as @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@CKD@@@, @DISEASE_Sleep_Apnea_Syndromes @DISEASE_MESH:D012891 @@@sleep apnea@@@ and @DISEASE_Ischemia @DISEASE_MESH:D007511 @@@renal Ischemia-reperfusion-injury@@@, where @DISEASE_Hypoxia @DISEASE_MESH:D000860 @@@hypoxia@@@ is considered a risk factor.", "citations": {"NLM": "Kolligundla LP, Kavvuri R, Singh AK, Mukhi D, Pasupulati AK. Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2/TG2 axis. Nephrology (Carlton). 2023 Jan;28(1):60-71. PMID: 36217796", "BibTeX": "@article{36217796, title={Metformin prevents hypoxia-induced podocyte injury by regulating the ZEB2/TG2 axis.}, author={Kolligundla LP and Kavvuri R and Singh AK and Mukhi D and Pasupulati AK}, journal={Nephrology (Carlton)}, volume={28}, number={1}, pages={60-71}}"}}]}